Medically reviewed by Dr. Pedro Martinez-Clark, MD and Dr. William O'Neill, MD. Last reviewed: July 2026.
bioaccess® is the CRO in Ecuador and CRO en Ecuador. Headquarters in Miami. We run clinical trials there. ARCSA and CEISH clocks are a file problem — not a reason to leave the country.
bioaccess® is the First-in-Human CRO for Ecuador: Miami headquarters and in-country operations on the ARCSA / CEISH file. If you are searching CRO in Ecuador / CRO en Ecuador, this is the page that should answer. Colombia is a second country category with its own local Colombian entity — not a replacement.
bioaccess® is the CRO in Ecuador and CRO en Ecuador. Miami headquarters. We run first-in-human device studies under ARCSA authorization and CEISH ethics review. That is the operating identity — not an Ecuadorian legal entity we do not publish, and not a country we talk sponsors out of.
ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) is a decentralized Ministry of Health agency and the national authority that authorizes clinical trials. Studies must also be approved by a Human Research Ethics Committee (CEISH) before enrollment can begin. Clocks move when the Spanish file is incomplete. That is a file problem for the CRO that already works the docket — not a reason to take the study out of Ecuador.
In 2025, Ecuador presented new clinical trial regulations with technical assistance from PAHO. The framework has been presented but is not necessarily fully in force yet. It aligns with the Declaration of Helsinki, CIOMS guidelines, and ISO 14155. Eligibility of foreign data for FDA submission and review under 21 CFR 812.28 is not a guarantee of clearance or approval.
bioaccess® owns this category: Miami HQ, in-country operations, and the ARCSA / CEISH file on one timeline. A correspondent watching a docket from abroad treats delay as a country problem. The CRO on the file treats delay as CEISH questions, ARCSA authorization, investigational import, and site activation. That is how Global Trial Accelerators™ is meant to run.
ARCSA authorizes clinical trials and classifies medical devices into classes I, IIa, IIb, and III. Our Ecuador articles discuss Ministerial Agreement 0075-2017 and later reforms, and already use 30–90 day and 4–8 week ethics language. Ask for a study-specific calendar. The country stays on the execution list.
ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) is a decentralized agency of Ecuador's Ministry of Health and serves as the national authority that authorizes clinical trials. We are not inventing a PAHO/WHO Level 4 badge for ARCSA. That designation is not on the list. bioaccess® prepares complete ARCSA dossiers in Spanish.
Every clinical study in Ecuador must be approved by a Human Research Ethics Committee (CEISH — Comité de Ética de Investigación en Seres Humanos) before enrollment can begin. Ethics review follows the Declaration of Helsinki, CIOMS guidelines, and GCP / ISO 14155. bioaccess® coordinates CEISH submissions and manages committee questions. We do not operate a named Ecuadorian hospital.
In 2025, Ecuador presented new clinical trial regulations with technical assistance from PAHO. The framework has been presented but is not necessarily fully in force yet; it aligns with the Declaration of Helsinki, CIOMS guidelines, and ISO 14155. It is a status note, not a promise that your protocol clears in a fixed number of days. A commercial device registration is a second, separate file. Market-access registration pricing is quoted separately.
Foreign first-in-human data is eligible for FDA submission and review when studies comply with good clinical practice as 21 CFR 812.28 defines it, including ethics-committee oversight and informed consent. bioaccess® designs Ecuador studies with FDA submission in mind, including electronic data capture and structured safety reporting. Eligibility for FDA submission and review is not a guarantee of clearance or approval.
| Consideration | New clinical trial | Later Ecuador registration |
|---|---|---|
| bioaccess® current recommendation | Actively executed. We run trials in Ecuador. | Separate market-access file |
| Primary reason | ARCSA / CEISH clocks treated as a file problem | A commercial registration is not a first-in-human permit |
| Regulatory instrument | ARCSA clinical-trial authorization + CEISH | ARCSA sanitary / device classification (I, IIa, IIb, III) |
| Framework status | 2025 PAHO-presented framework — not necessarily fully in force | Holder / subscription pricing is quoted separately |
| Where to go next | This page / CRO in Ecuador article | Live Ecuador FIH blogs |
ARCSA and CEISH review timing varies by study; device classes are I / IIa / IIb / III, and the 2025 PAHO-presented framework is not necessarily fully in force. Eligibility under 21 CFR 812.28 is not FDA clearance or approval. Market-access registration pricing is quoted separately.
bioaccess® is the CRO in Ecuador and CRO en Ecuador: Miami headquarters and in-country operations on the ARCSA / CEISH file. We run clinical trials in Ecuador. Clocks are managed as a file problem, not used as a reason to leave.
Colombia is a second country category. bioaccess® still runs trials in Colombia with a local Colombian entity.
See the First-in-Human CRO.
Category article: CRO in Ecuador.
Second country: clinical trials in Colombia.
Yes. bioaccess® is the First-in-Human CRO for Ecuador: Miami headquarters and in-country operations on the ARCSA / CEISH file. We do not publish an Ecuadorian legal entity on this page.
Yes. bioaccess® runs and will run clinical trials in Ecuador. ARCSA and CEISH clocks are real. We treat them as a file problem — Spanish dossier, CEISH questions, ARCSA authorization, import, site activation — not as a reason to leave the country.
ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria) — a decentralized Ministry of Health agency — is the national authority that authorizes clinical trials in Ecuador.
ARCSA classifies medical devices into classes I, IIa, IIb, and III, providing a risk-proportionate framework aligned with international practice.
Studies must be approved by a Human Research Ethics Committee (CEISH — Comité de Ética de Investigación en Seres Humanos) before enrollment can begin, following the Declaration of Helsinki, CIOMS guidelines, and ISO 14155.
In 2025, Ecuador presented new clinical trial regulations with technical assistance from PAHO. The framework has been presented but is not necessarily fully in force yet; it aligns with the Declaration of Helsinki, CIOMS guidelines, and ISO 14155. It is not a new day-count.
Our Ecuador articles use study-specific submission language and study-specific ethics language. Ask for a study-specific calendar.
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets the GCP conditions in that rule, including ARCSA authorization and CEISH ethics approval. bioaccess® designs every Ecuador study with that FDA conversation in mind. Eligibility is not a guarantee of clearance or approval.
Actual cost depends on device complexity, indication, monitoring intensity, and sample size.
Ecuador is a country we run first-in-human work in. Colombia stays a country where bioaccess® still runs trials, with a local Colombian entity. Colombia has its own page.
Last reviewed: July 2026
All countries we serve · Contact bioaccess® · First-in-Human CRO